Patrick S. Lee

Patrick S. Lee

Auto-generated profile, based on publicly available information

Patrick S. Lee

Novartis Institutes for Biomedical Research

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2003 in The Journal of Physical Chemistry A
Verified
Journal Article
Closed access
VGVildan Guner
Vildan Guner
KKKelli S. Khuong
Kelli S. Khuong
ALAndrew G. Leach
Andrew G. Leach
PLPatrick S. Lee
Patrick S. Lee
MBMichael D. Bartberger
Michael D. Bartberger
KHK. N. Houk
K. N. Houk

13 May 2019 in ACS Chemical Biology
Verified
Journal Article
Closed access
CWCarl C. Ward
Carl C. Ward
JKJordan I. Kleinman
Jordan I. Kleinman
SBScott M. Brittain
Scott M. Brittain
PLPatrick S. Lee
Patrick S. Lee
CCClive Yik Sham Chung
Clive Yik Sham Chung
DNDaniel K. Nomura
Daniel K. Nomura


1 December 2009 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
SBSean G. Buchanan
Sean G. Buchanan
JHJorg Hendle
Jorg Hendle
PLPatrick S. Lee
Patrick S. Lee
CSChristopher R. Smith
Christopher R. Smith
PBPierre-Yves Bounaud
Pierre-Yves Bounaud
SRSiegfried H. Reich
Siegfried H. Reich
The MET receptor tyrosine kinase has emerged as an important target for the development of novel cancer therapeutics. Activation of MET by mutation or gene amplification has been linked to kidney, gastric, and lung cancers. In other cancers, such as glioblastoma, autocrine activation of MET has been demonstrated. Several classes of ATP-competitive inhibitor have been described, which inhibit MET but also other kinases. Here, we describe SGX523, a novel, ATP-competitive kinase inhibitor remarkable for its exquisite selectivity for MET. SGX523 potently inhibited MET with an IC50 of 4 nmol/L and is >1,000-fold selective versus the >200-fold selectivity of other protein kinases tested in biochemical assays. Crystallographic study revealed that SGX523 stabilizes MET in a unique inactive conformation that is inaccessible to other protein kinases, suggesting an explanation for the selectivity. SGX523 inhibited MET-mediated signaling, cell proliferation, and cell migration at nanomolar concentrations but had no effect on signaling dependent on other protein kinases, including the closely related RON, even at micromolar concentrations. SGX523 inhibition of MET in vivo was associated with the dose-dependent inhibition of growth of tumor xenografts derived from human glioblastoma and lung and gastric cancers, confirming the dependence of these tumors on MET catalytic activity. Our results show that SGX523 is the most selective inhibitor of MET catalytic activity described to date and is thus a useful tool to investigate the role of MET kinase in cancer without the confounding effects of promiscuous protein kinase inhibition. [Mol Cancer Ther 2009;8(12):3181–90]

1 April 2003 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
PLPatrick S. Lee
Patrick S. Lee
XZXiyun Zhang
Xiyun Zhang
KHK. N. Houk
K. N. Houk

22 April 2003 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
PLPatrick S. Lee
Patrick S. Lee
SSShogo Sakai
Shogo Sakai
PHPeter Hörstermann
Peter Hörstermann
WRWolfgang R. Roth
Wolfgang R. Roth
EKE. Adam Kallel
E. Adam Kallel
KHK. N. Houk
K. N. Houk